NEW YORK (GenomeWeb) – Roka Bioscience reported after the close of the market Thursday that its third quarter revenues nearly tripled year over year as it trimmed its net loss.

The Warren, NJ-based molecular diagnostics firm reported revenues of $1.5 million for the three months ended Sept. 30, compared to $556,000 for the third quarter of 2013. It fell short of the average Wall Street estimate of $2.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.